FLOT Combined With PD-1 in the First-line Treatment of Patients With Advanced Gastric Cancer and Peritoneal Metastasis
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
In this study, patients with advanced gastric adenocarcinoma whose peritoneal metastasis and
peritoneal nodule pathologically confirmed metastasis and/or exfoliative cytology were
confirmed as the clinical stage of peritoneal metastasis, who had not received treatment
before, were invited to participate in the study.To evaluate the surgical conversion rate and
tumor regression grade (TRG grade) of patients with stage gastric cancer with peritoneal
metastasis using docetaxel, oxaliplatin, fluorouracil (FLOT regimen) combined with
teriprizumab (PD-1).
Phase:
N/A
Details
Lead Sponsor:
Guangdong Provincial Hospital of Traditional Chinese Medicine